Stockscreener 앱 받기
40.18
11.67%
4.20
시간 외 거래:
40.88
0.70
+1.74%
전일 마감가:
$35.98
열려 있는:
$35.96
하루 거래량:
1.70M
Relative Volume:
0.82
시가총액:
$764.17M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-27.52
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+34.56%
1개월 성능:
+78.10%
6개월 성능:
+4,584%
1년 성능:
+3,456%
1일 변동 폭
$34.62
$40.45
1주일 범위
$27.87
$40.45
52주 변동 폭
$0.432
$40.45
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
40.18 | 684.29M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Can Nektar Therapeutics recover in the next quarter2025 Geopolitical Influence & Community Verified Trade Signals - Newser
What’s the beta of Nektar Therapeutics stockJuly 2025 Summary & Weekly Top Gainers Alerts - خودرو بانک
What is the dividend yield of Nektar TherapeuticsWatch List & Pattern Based Trade Signal System - خودرو بانک
Measuring Nektar Therapeutics’s beta against major indicesJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - Newser
Top chart patterns to watch in Nektar TherapeuticsWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
Real time alert setup for Nektar Therapeutics performanceJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Why Nektar Therapeutics Rippled Higher This Week - sharewise.com
What is Nektar Therapeutics’s TAM (Total Addressable Market)Earnings Overview Report & Stepwise Swing Trade Plans - خودرو بانک
Nektar Therapeutics stock trend forecast2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
Nektar Therapeutics (NKTR) Surges on Rival's Disappointing Resul - GuruFocus
Combining machine learning predictions for Nektar TherapeuticsMarket Sentiment Report & Weekly Setup with High ROI Potential - Newser
Here's Why Shares in PTC Therapeutics Soared This Week - AOL.com
What does recent volatility data suggest for Nektar TherapeuticsJuly 2025 Summary & Real-Time Volume Triggers - Newser
Nektar Therapeutics (NKTR) Surges 26.02% as Sanofi's Underwhelming AD Trial Highlights Competitive Edge - AInvest
Candlestick signals on Nektar Therapeutics stock todayPrice Action & Precise Entry and Exit Recommendations - Newser
News impact scoring models applied to Nektar TherapeuticsJuly 2025 Summary & Daily Stock Trend Reports - Newser
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Long term hold vs stop loss in Nektar Therapeutics2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
Can Nektar Therapeutics expand into new marketsEarnings Risk Summary & Reliable Volume Spike Alerts - خودرو بانک
Analysts postive on Nektar opportunity after Sanofi data - Investing.com
What's Going On With Nektar Therapeutics Stock On Thursday?Nektar Therapeutics (NASDAQ:NKTR) - Benzinga
Nektar Therapeutics Surges 19.5%: What's Fueling the Sharp Intraday Move? - AInvest
Nektar Therapeutics Soars 23.4% on FDA Fast Track Designation and Analyst Upgrades—Can This Momentum Sustain? - AInvest
Nektar Therapeutics to Participate in Two Investor Conferences in September - Eastern Progress
Nektar Therapeutics Shares Rise Amid Sanofi's Disappointing Eczema Drug Results - AInvest
Nektar Therapeutics Shares Jump as Sanofi's Eczema Drug Results Miss Expectations in Study - MarketScreener
Nektar Therapeutics Shares Soar After Sanofi’s Amlitelimab Falls Short - MSN
Nektar Therapeutics stock jumps after Sanofi’s amlitelimab data disappoints - Investing.com
Nektar Therapeutics Soars 14.05% on FDA Fast Track Designation - AInvest
Multi asset correlation models including Nektar Therapeutics2025 Support & Resistance & Daily Profit Maximizing Trade Tips - Newser
Using Ichimoku Cloud for Nektar Therapeutics technicalsWeekly Trade Report & Detailed Earnings Play Strategies - Newser
Published on: 2025-09-03 23:43:22 - Newser
Nektar Therapeutics’ Strategic Investor Engagement and Pipeline Progress - AInvest
Biotech Leader Nektar Therapeutics Set for Double Investor Conference Appearances in September 2025 - Stock Titan
Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu - Barchart.com
Will Nektar Therapeutics outperform the market in YEARMarket Volume Report & Low Risk High Reward Trade Ideas - خودرو بانک
Published on: 2025-09-03 09:08:30 - Newser
Trend analysis for Nektar Therapeutics this weekFed Meeting & Comprehensive Market Scan Reports - Newser
Using fundamentals and technicals on Nektar Therapeutics2025 Volatility Report & Community Shared Stock Ideas - Newser
Nektar Therapeutics stock trend outlook and recovery path2025 AllTime Highs & Reliable Trade Execution Plans - Newser
Will Nektar Therapeutics announce a stock splitQuarterly Risk Review & Reliable Intraday Trade Plans - خودرو بانک
How to manage a losing position in Nektar TherapeuticsQuarterly Trade Report & Low Volatility Stock Recommendations - Newser
Should you wait for a breakout in Nektar TherapeuticsWeekly Profit Recap & Free Safe Entry Trade Signal Reports - Newser
Comparing Nektar Therapeutics in custom built stock radarsWeekly Market Summary & Momentum Based Trading Ideas - Newser
Nektar Therapeutics stock outlook for YEARJuly 2025 PreEarnings & Fast Entry High Yield Tips - Newser
Is Nektar Therapeutics stock ready for a breakout2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How to monitor Nektar Therapeutics with trend dashboardsMarket Volume Summary & Fast Exit and Entry Strategy Plans - Newser
Automated trading signals detected on Nektar TherapeuticsPortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Will Nektar Therapeutics benefit from macro trendsJuly 2025 Momentum & Expert Curated Trade Setup Alerts - Newser
how to manage a losing position in nektar therapeuticsEarnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
넥타테라퓨틱스 주식 (NKTR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer |
Sep 02 '25 |
Sale |
30.10 |
485 |
14,598 |
19,183 |
| ROBIN HOWARD W | President & CEO |
Sep 02 '25 |
Sale |
30.16 |
1,500 |
45,240 |
67,840 |
1.40%
자본화:
|
볼륨(24시간):